CA3204296A1 - Polypeptides and uses thereof - Google Patents
Polypeptides and uses thereofInfo
- Publication number
- CA3204296A1 CA3204296A1 CA3204296A CA3204296A CA3204296A1 CA 3204296 A1 CA3204296 A1 CA 3204296A1 CA 3204296 A CA3204296 A CA 3204296A CA 3204296 A CA3204296 A CA 3204296A CA 3204296 A1 CA3204296 A1 CA 3204296A1
- Authority
- CA
- Canada
- Prior art keywords
- xaa
- c18diacid
- amide
- cntatc
- aib
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063125996P | 2020-12-16 | 2020-12-16 | |
| US63/125,996 | 2020-12-16 | ||
| PCT/EP2021/086034 WO2022129254A1 (en) | 2020-12-16 | 2021-12-15 | Polypeptides and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3204296A1 true CA3204296A1 (en) | 2022-06-23 |
Family
ID=79287870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3204296A Pending CA3204296A1 (en) | 2020-12-16 | 2021-12-15 | Polypeptides and uses thereof |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20240067693A1 (https=) |
| EP (1) | EP4263586B1 (https=) |
| JP (2) | JP7767428B2 (https=) |
| KR (1) | KR20230120134A (https=) |
| CN (1) | CN116685599A (https=) |
| AR (1) | AR124391A1 (https=) |
| AU (2) | AU2021399076B2 (https=) |
| CA (1) | CA3204296A1 (https=) |
| CL (1) | CL2023001719A1 (https=) |
| CO (1) | CO2023009066A2 (https=) |
| CR (1) | CR20230311A (https=) |
| EC (1) | ECSP23052600A (https=) |
| IL (1) | IL303578A (https=) |
| MX (1) | MX2023007288A (https=) |
| TW (1) | TW202241933A (https=) |
| WO (1) | WO2022129254A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240067693A1 (en) | 2020-12-16 | 2024-02-29 | Medimmune Limited | Polypeptides and uses thereof |
| WO2022159395A1 (en) | 2021-01-20 | 2022-07-28 | Viking Therapeutics, Inc. | Compositions and methods for the treatment of metabolic and liver disorders |
| MX2024003236A (es) | 2021-09-15 | 2024-06-19 | Viking Therapeutics Inc | Composiciones y metodos para el tratamiento de trastornos metabolicos y hepaticos. |
| US12116388B2 (en) | 2022-12-22 | 2024-10-15 | Novo Nordisk A/S | Amylin receptor agonists |
| AU2024218747A1 (en) * | 2023-02-10 | 2025-08-28 | Hangzhou Sciwind Biosciences Co., Ltd. | Polypeptide and derivative thereof, composition, and use thereof |
| JP7755031B2 (ja) | 2023-11-30 | 2025-10-15 | ノヴォ ノルディスク アー／エス | Ｇｌｐ－１、ｇｉｐ、およびアミリン受容体の三重作動薬 |
| WO2025147628A2 (en) * | 2024-01-05 | 2025-07-10 | Indiana University Research And Technology Corporation | Dual amylin calcitonin receptor agonists |
| WO2025242620A1 (en) | 2024-05-20 | 2025-11-27 | Medimmune Limited | Polypeptide combinations and uses thereof |
| WO2026058194A1 (en) | 2024-09-12 | 2026-03-19 | Medimmune Limited | Polypeptide dosage regimens |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004051014A1 (de) | 2004-10-20 | 2006-04-27 | Rwth Aachen | Chemisch modifizierte Peptidanaloga |
| JP5252435B2 (ja) | 2006-03-15 | 2013-07-31 | ノボ・ノルデイスク・エー／エス | アミリン誘導体 |
| EP2036923A1 (en) | 2007-09-11 | 2009-03-18 | Novo Nordisk A/S | Improved derivates of amylin |
| CN102197049B (zh) * | 2008-10-21 | 2015-03-25 | 诺沃-诺迪斯克有限公司 | 胰岛淀粉样多肽衍生物 |
| US9205135B2 (en) * | 2009-09-22 | 2015-12-08 | University Of Miami | Podocyte pH modulation and uses thereof |
| US20140249076A1 (en) | 2011-10-18 | 2014-09-04 | Astrazeneca Pharmaceuticals Lp | Amylin-calcitonin chimeric peptides conjugated to duration enhancing moieties |
| SG10201805039UA (en) * | 2013-12-13 | 2018-07-30 | Medimmune Ltd | Protease resistant peptides |
| JP6730278B2 (ja) | 2014-11-27 | 2020-07-29 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１誘導体及びその使用 |
| AR116632A1 (es) | 2018-10-11 | 2021-05-26 | Intarcia Therapeutics Inc | Polipéptidos análogos de la amilina humana y sus métodos de uso |
| WO2020225781A1 (en) | 2019-05-08 | 2020-11-12 | Auckland Uniservices Limited | Peptide conjugate amylin agonists and uses thereof |
| US20240067693A1 (en) | 2020-12-16 | 2024-02-29 | Medimmune Limited | Polypeptides and uses thereof |
-
2021
- 2021-12-15 US US18/257,756 patent/US20240067693A1/en active Pending
- 2021-12-15 WO PCT/EP2021/086034 patent/WO2022129254A1/en not_active Ceased
- 2021-12-15 MX MX2023007288A patent/MX2023007288A/es unknown
- 2021-12-15 EP EP21839935.0A patent/EP4263586B1/en active Active
- 2021-12-15 AU AU2021399076A patent/AU2021399076B2/en active Active
- 2021-12-15 CN CN202180084231.3A patent/CN116685599A/zh active Pending
- 2021-12-15 CA CA3204296A patent/CA3204296A1/en active Pending
- 2021-12-15 KR KR1020237023385A patent/KR20230120134A/ko active Pending
- 2021-12-15 IL IL303578A patent/IL303578A/en unknown
- 2021-12-15 US US17/551,701 patent/US12371464B2/en active Active
- 2021-12-15 CR CR20230311A patent/CR20230311A/es unknown
- 2021-12-15 JP JP2023536144A patent/JP7767428B2/ja active Active
- 2021-12-16 TW TW110147305A patent/TW202241933A/zh unknown
- 2021-12-16 AR ARP210103535A patent/AR124391A1/es unknown
-
2023
- 2023-06-14 CL CL2023001719A patent/CL2023001719A1/es unknown
- 2023-07-06 CO CONC2023/0009066A patent/CO2023009066A2/es unknown
- 2023-07-12 EC ECSENADI202352600A patent/ECSP23052600A/es unknown
-
2024
- 2024-10-03 AU AU2024227071A patent/AU2024227071A1/en active Pending
-
2025
- 2025-02-12 US US19/052,168 patent/US20250289860A1/en active Pending
- 2025-10-29 JP JP2025182255A patent/JP2026031965A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CR20230311A (es) | 2023-09-01 |
| IL303578A (en) | 2023-08-01 |
| MX2023007288A (es) | 2023-07-03 |
| CO2023009066A2 (es) | 2023-07-10 |
| AU2021399076A1 (en) | 2023-07-27 |
| CN116685599A (zh) | 2023-09-01 |
| CL2023001719A1 (es) | 2024-01-26 |
| AU2024227071A1 (en) | 2024-10-24 |
| KR20230120134A (ko) | 2023-08-16 |
| US20240067693A1 (en) | 2024-02-29 |
| EP4263586A1 (en) | 2023-10-25 |
| WO2022129254A1 (en) | 2022-06-23 |
| EP4263586B1 (en) | 2026-03-11 |
| AR124391A1 (es) | 2023-03-22 |
| JP2023554046A (ja) | 2023-12-26 |
| US20220204580A1 (en) | 2022-06-30 |
| TW202241933A (zh) | 2022-11-01 |
| AU2021399076A9 (en) | 2024-07-18 |
| JP2026031965A (ja) | 2026-02-25 |
| AU2021399076B2 (en) | 2024-07-11 |
| US12371464B2 (en) | 2025-07-29 |
| US20250289860A1 (en) | 2025-09-18 |
| JP7767428B2 (ja) | 2025-11-11 |
| ECSP23052600A (es) | 2023-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021399076B2 (en) | Polypeptides and uses thereof | |
| US12371465B2 (en) | Incretin analogs and uses thereof | |
| CA3084004C (en) | Incretin analogs and uses thereof | |
| KR102824306B1 (ko) | 인크레틴 유사체 및 그의 용도 | |
| CN102197049B (zh) | 胰岛淀粉样多肽衍生物 | |
| EP3074032B1 (en) | Fatty acid derivatives of dimeric inhibitors of psd-95 | |
| US20240270821A1 (en) | Gip/glp1/gcg tri-receptor agonists and uses thereof | |
| EA050089B1 (ru) | Полипептиды и варианты их применения | |
| HK1229227B (en) | Fatty acid derivatives of dimeric inhibitors of psd-95 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20251103 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20251103 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251103 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251124 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251124 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251125 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260115 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260115 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260115 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260115 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260116 |